The Relationship Between Body Mass Index And Age At Hepatocellular Carcinoma Onset
Posted on: Tuesday, 15 March 2011, 15:40 CDT
The incidence and mortality associated with hepatocellular carcinoma (HCC) have been increasing worldwide, and hepatitis C virus (HCV) infection plays an important role in the pathogenesis of HCC. Previous studies have suggested that host factors, such as sex, alcohol consumption, smoking, diabetes mellitus, and obesity, are important risk factors for HCC. Meanwhile, it has been reported that HCV infection causes insulin resistance and leads to oxidative stress, potentiating fibrosis and hepatic carcinogenesis. However, the factors that influence the development of HCC in HCV-infected patients remain largely unknown.
A research article published on February 21, 2011 in the World Journal of Gastroenterology addresses this question. The authors hypothesized that obesity influences the time to onset of HCC related to HCV infection, which is reflected in the patient's age at onset. To test this hypothesis, they investigated the relationship between body mass index (BMI) and lifestyle factors and age at onset of HCC in HCV-infected patients.
The research showed that the underweight patients (BMI < 18.5 kg/m2), tended to be older at HCC onset than patients within the normal weight range (BMI 18.5 kg/m2).
The results suggest that achieving an adequate body weight along with a reduction of alcohol intake in patients with chronic hepatitis C could help prevent hepatic carcinogenesis.
---
On the Net:
World Journal of Gastroenterology
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment